MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

WIB_icon

Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies

The oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib appeared to be active and tolerable at a range of doses and across a variety of...

Could Adding Sotatercept to Ruxolitinib Improve MPN-Associated MF and Anemia?

The JAK1 inhibitor ruxolitinib is the only therapy approved by the U.S. Food and Drug Administration for myelofibrosis (MF), but it often worsens anemia,...

Should Patients With Myelodysplastic Syndromes Undergo Transplant?

For patients with myelodysplastic syndromes (MDS), hematopoietic cell transplantation (HCT) is the only potentially curative option, but the rates of transplant-related morbidity and mortality...

CMS Expands Coverage for Hematopoietic Cell Transplantation: Proceed with Cautious Optimism

The recent decision by the Centers for Medicare and Medicaid Services (CMS) to cover allogeneic hematopoietic cell transplantation (alloHCT) for eligible patients with sickle...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.